#1 Clinical Trials Search in Europe

Ponsegromab

Ponsegromab is an investigational drug currently being studied in clinical trials for its potential benefits in treating various conditions, including cancer-related cachexia, heart failure, and its effects on healthy individuals. These trials aim to evaluate the drug’s safety, efficacy, and how it interacts with the body across different patient populations.

Table of Contents

What is Ponsegromab?

Ponsegromab, also known by its research code PF-06946860, is a new medication currently being studied for its potential to treat various medical conditions[1]. It is an experimental drug that is not yet approved for general use but is undergoing clinical trials to evaluate its effectiveness and safety.

Medical Conditions Treated by Ponsegromab

Ponsegromab is being investigated for several medical conditions:

  • Cancer-related cachexia: This is a condition where cancer patients experience severe weight loss, muscle wasting, and loss of appetite[1].
  • Heart failure: A condition where the heart can’t pump blood effectively to meet the body’s needs[3].
  • Specific cancer types: Including non-small cell lung cancer, pancreatic cancer, and colorectal cancer[1].

Additionally, Ponsegromab is being studied for its effects on symptoms often associated with these conditions, such as:

  • Loss of appetite
  • Fatigue
  • Nausea and vomiting
  • Physical limitations

How Ponsegromab Works

Ponsegromab targets a protein in the body called GDF-15 (Growth Differentiation Factor 15)[1]. GDF-15 is often elevated in patients with certain cancers and heart failure. By targeting this protein, researchers hope that Ponsegromab can help alleviate symptoms and improve quality of life for patients with these conditions.

In cancer patients with cachexia, Ponsegromab aims to improve body weight, physical activity, and appetite[1]. For heart failure patients, the drug is being studied for its potential to improve symptoms, physical function, and overall quality of life[3].

How Ponsegromab is Administered

Ponsegromab is given as a subcutaneous injection, which means it’s injected just under the skin[2]. The injection can be given in various areas of the body, such as:

  • The front of the thigh
  • The abdomen (stomach area)
  • The outer area of the upper arm

The frequency of injections varies depending on the specific clinical trial, but it’s typically administered every four weeks[1][3].

Current Clinical Trials

Ponsegromab is currently being studied in several clinical trials:

  1. Cancer and Cachexia Study: This is a Phase 2 trial looking at the effects of Ponsegromab in cancer patients with cachexia and elevated GDF-15 levels[1].
  2. Heart Failure Study: This is another Phase 2 trial investigating Ponsegromab’s effects on symptoms, function, and quality of life in heart failure patients[3].
  3. Pharmacokinetic Study: This is a Phase 1 study in healthy Chinese adults to understand how the body processes and eliminates Ponsegromab[2].

These trials are crucial for determining the effectiveness and safety of Ponsegromab before it can be considered for approval as a treatment.

Safety and Side Effects

As with all medications, researchers are closely monitoring the safety of Ponsegromab. The clinical trials are designed to identify any potential side effects or safety concerns. Some of the aspects being monitored include:

  • Adverse events (any unexpected medical occurrences during the trial)
  • Changes in laboratory test results
  • Changes in vital signs
  • Electrocardiogram (ECG) abnormalities

It’s important to note that as Ponsegromab is still in the testing phase, not all potential side effects may be known. Patients participating in clinical trials are closely monitored for any unexpected reactions[1][3].

Aspect Details
Drug Name Ponsegromab (also known as PF-06946860)
Administration Method Subcutaneous injection
Conditions Studied Cancer-related cachexia, Heart failure, Effects on healthy individuals
Key Outcomes Measured Safety, Efficacy, Pharmacokinetics, Quality of life, Physical function, Symptom burden
Study Designs Phase 1 and Phase 2 trials, Double-blind placebo-controlled, Open-label studies
Patient Populations Cancer patients with cachexia, Heart failure patients, Healthy adults
Notable Assessments Body weight changes, Physical activity, Quality of life questionnaires, Blood sample analysis, Adverse event monitoring

FAQ

  • What is Ponsegromab? Ponsegromab is an investigational drug being studied for its potential benefits in treating conditions such as cancer-related cachexia and heart failure. It is administered through subcutaneous injections and is being evaluated for its safety, efficacy, and how it interacts with the body.
  • What conditions is Ponsegromab being studied for? Ponsegromab is currently being studied in clinical trials for cancer-related cachexia (in patients with non-small cell lung cancer, pancreatic cancer, and colorectal cancer), heart failure, and its effects on healthy individuals.
  • How is Ponsegromab administered? Ponsegromab is administered through subcutaneous injections, which means it is injected under the skin. The frequency of administration varies depending on the study, but it is often given every 4 weeks.
  • What are the main goals of the Ponsegromab clinical trials? The main goals of the Ponsegromab clinical trials include evaluating its safety and tolerability, assessing its efficacy in treating specific conditions, understanding how the drug is processed by the body (pharmacokinetics), and measuring its effects on various symptoms and quality of life measures.
  • Are there any known side effects of Ponsegromab? As Ponsegromab is still in clinical trials, its full side effect profile is not yet known. The trials are designed to monitor and record any adverse events, including treatment-emergent adverse events, serious adverse events, and changes in laboratory results or vital signs. This information will help determine the safety profile of the drug.

Ongoing Clinical Trials on Ponsegromab

  • A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

    Recruiting

    4 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland +2

  • Study of ponsegromab for patients with cancer cachexia and elevated GDF-15 levels

    Not recruiting

    2 1
    Investigated drugs:
    Bulgaria Poland Slovakia Spain

  • Study on the Effects of Ponsegromab on Quality of Life and Safety in Adults with Heart Failure

    Not recruiting

    2 1
    Investigated drugs:
    Czechia Germany Hungary Poland Spain

Glossary

  • Cachexia: A complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. It is commonly seen in patients with advanced cancer and other chronic diseases.
  • GDF-15: Growth Differentiation Factor 15, a protein that is elevated in various conditions including cancer and heart failure. Some studies are focusing on patients with elevated GDF-15 levels.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Placebo: An inactive substance or treatment that looks like the drug being tested but contains no active ingredient.
  • Double-blind study: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • Quality of life: A measure of an individual's well-being that includes physical, mental, and social aspects of their life.
  • Kansas City Cardiomyopathy Questionnaire (KCCQ): A self-administered questionnaire that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life for patients with heart failure.

References